Curcumin compound reactivates Epstein–Barr virus, offering safer cancer therapy

A novel curcumin derivative, C210, activates the Epstein–Barr virus (EBV) lytic cycle without producing infectious virions by disrupting HSP90. This discovery opens avenues for safer EBV-positive cancer therapies.

Immunotherapy before and after surgery benefits NSCLC patients

People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of

September 9, 2024

EVT on Large Core Strokes: Sobering Results for the Oldest Old

The older the patient, the worse the functional outcome tended to be after endovascular thrombectomy (EVT) for an acute ischemic stroke with a large infarct,

August 13, 2024

Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more

March 12, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.